Compare Stocks → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:BLCMNASDAQ:CYADNASDAQ:GEMPOTCMKTS:HBPCFNASDAQ:NBSE Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLCMBellicum Pharmaceuticals$0.07-6.6%$0.08$0.06▼$1.31$727K1.3922,874 shs6,000 shsCYADCelyad Oncology$0.60$0.67$0.46▼$3.07$15.91MN/AN/A3,009 shsGEMPGemphire Therapeutics$3.37-2.0%$4.97$0.24▼$1.49$50.12M2.82127,174 shs20,562 shsHBPCFHelix BioPharma$0.14$0.14$0.14▼$0.15$31.59M-0.1900 shsN/ANBSENeuBase Therapeutics$0.41-4.6%$0.70$0.39▼$4.80$1.54M0.83209,105 shs157,466 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLCMBellicum Pharmaceuticals0.00%0.00%0.00%-25.20%-77.84%CYADCelyad Oncology0.00%0.00%0.00%0.00%-6.25%GEMPGemphire Therapeutics0.00%-6.65%-24.44%+1.81%+394.86%HBPCFHelix BioPharma0.00%0.00%-6.96%-5.03%-5.81%NBSENeuBase Therapeutics-4.42%-1.49%-60.10%-32.99%-86.54%top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (Ad)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBLCMBellicum PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACYADCelyad OncologyN/AN/AN/AN/AN/AN/AN/AN/AGEMPGemphire TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AHBPCFHelix BioPharmaN/AN/AN/AN/AN/AN/AN/AN/ANBSENeuBase TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLCMBellicum PharmaceuticalsN/AN/AN/AN/ACYADCelyad OncologyN/AN/AN/AN/AGEMPGemphire TherapeuticsN/AN/AN/AN/AHBPCFHelix BioPharmaN/AN/AN/AN/ANBSENeuBase TherapeuticsN/AN/AN/AN/ASales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLCMBellicum Pharmaceuticals$1.50M0.48N/AN/A$0.23 per share0.33CYADCelyad Oncology$110K144.65N/AN/A$0.20 per share3.00GEMPGemphire TherapeuticsN/AN/AN/AN/A$0.54 per shareN/AHBPCFHelix BioPharmaN/AN/AN/AN/AN/AN/ANBSENeuBase TherapeuticsN/AN/AN/AN/A$11.04 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLCMBellicum Pharmaceuticals-$24.97MN/A0.00∞N/AN/AN/A-157.93%N/ACYADCelyad Oncology-$9.14MN/A0.00∞N/AN/AN/AN/AN/AGEMPGemphire Therapeutics-$23.64MN/A0.00∞N/AN/A-419.70%-173.05%N/AHBPCFHelix BioPharma-$4.69M-$0.04N/A∞N/AN/A-817.64%-308.71%6/12/2024 (Estimated)NBSENeuBase Therapeutics-$4.37M-$7.70N/A∞N/AN/A-99.74%-60.13%5/9/2024 (Estimated)DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLCMBellicum PharmaceuticalsN/AN/AN/AN/AN/ACYADCelyad OncologyN/AN/AN/AN/AN/AGEMPGemphire TherapeuticsN/AN/AN/AN/AN/AHBPCFHelix BioPharmaN/AN/AN/AN/AN/ANBSENeuBase TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLCMBellicum PharmaceuticalsN/A3.043.04CYADCelyad OncologyN/AN/AN/AGEMPGemphire TherapeuticsN/A0.670.67HBPCFHelix BioPharmaN/A1.461.46NBSENeuBase TherapeuticsN/A2.872.87OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLCMBellicum Pharmaceuticals4.93%CYADCelyad OncologyN/AGEMPGemphire Therapeutics17.53%HBPCFHelix BioPharmaN/ANBSENeuBase Therapeutics12.37%Insider OwnershipCompanyInsider OwnershipBLCMBellicum Pharmaceuticals10.30%CYADCelyad Oncology0.94%GEMPGemphire Therapeutics22.70%HBPCFHelix BioPharma7.60%NBSENeuBase Therapeutics13.90%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBLCMBellicum Pharmaceuticals139.72 million8.72 millionNot OptionableCYADCelyad Oncology9526.52 million26.28 millionNot OptionableGEMPGemphire Therapeutics914.87 millionN/ANot OptionableHBPCFHelix BioPharma9229.44 million212.00 millionNot OptionableNBSENeuBase Therapeutics373.75 million3.23 millionNot OptionableCYAD, GEMP, HBPCF, NBSE, and BLCM HeadlinesSourceHeadlineNeuBase Therapeutics, Inc.: NeuBase Therapeutics Announces Receipt of Notice from Nasdaqfinanznachrichten.de - April 6 at 8:58 AMNeuBase Therapeutics Announces Receipt of Notice from Nasdaqglobenewswire.com - April 5 at 4:05 PMOnce-promising Pittsburgh biotech firm shutting down for goodtechnical.ly - March 27 at 8:33 PMWhy Neubase Therapeutics (NBSE) Shares Are Nosedivingmsn.com - March 27 at 10:32 AMNeuBase Therapeutics, ABVC BioPharma, Stoke Therapeutics among healthcare moversmsn.com - March 26 at 10:47 AMWhy Is NeuBase Therapeutics (NBSE) Stock Down 58% Today?investorplace.com - March 26 at 9:08 AMNeuBase Therapeutics sets shareholder meeting on dissolution planbizjournals.com - March 25 at 7:44 PMNeuBase Therapeutics Incedition.cnn.com - February 26 at 9:46 AMNeuBase Therapeutics, Inc. (NBSE)finance.yahoo.com - February 20 at 1:40 PMNeuBase Therapeutics Inc (O7P.BE)ca.finance.yahoo.com - January 20 at 12:17 AMMonitoring NeuBase Therapeutics Inc (NBSE) after recent insider movementsknoxdaily.com - January 1 at 2:48 PMCMU halts licensing agreement with NeuBase Therapeuticsbizjournals.com - December 22 at 7:16 PMPsychemedics Corporation Appoints Daniella Mehalik as VP - Financefinance.yahoo.com - November 27 at 10:19 AMNeuBase Therapeutics Inc NBSEmorningstar.com - November 6 at 11:41 PMNeuBase Therapeutics: Other Eventscbonds.com - October 21 at 8:32 AMNeuBase Therapeutics, Inc. (NBSE.MX)finance.yahoo.com - October 6 at 8:56 AMNeuBase Therapeutics Inc. (NBSE) gets rating Reiterated from H.C. Wainwrightknoxdaily.com - September 20 at 6:31 PMMassive Insider Trade At NeuBase Therapeuticsbenzinga.com - September 12 at 3:51 PMNeuBase falls after largest shareholder disposes of part stakemsn.com - September 12 at 3:51 PMNeuBase Therapeutics Issues Statement Regarding Filing By Shareholderfinance.yahoo.com - September 8 at 11:10 AMWhy Is NeuBase Therapeutics (NBSE) Stock Up 19% Today?markets.businessinsider.com - September 6 at 9:07 AMNBSE’s short interest falls to 41130.0 sharesknoxdaily.com - August 25 at 4:34 PMAnalysts Conflicted on These Healthcare Names: NeuBase Therapeutics (NBSE) and Centessa Pharmaceuticals (CNTA)markets.businessinsider.com - August 16 at 7:45 AMNeuBase Therapeutics (NASDAQ: NBSE)fool.com - August 6 at 6:46 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBellicum PharmaceuticalsNASDAQ:BLCMBellicum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also include BPX-603, an autologous dual-switch GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing human epidermal growth factor receptor 2 antigen. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is based in Houston, Texas.Celyad OncologyNASDAQ:CYADCelyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.Gemphire TherapeuticsNASDAQ:GEMPGemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and nonalcoholic fatty liver disease (NAFLD/NASH). The company is developing gemcabene, a novel, once-daily, and oral therapy for dyslipidemia conditions where patients are unable to reach their lipid lowering goals, including patients already receiving maximally tolerated statin therapy. It also completed three Phase IIb clinical trials for gemcabene in homozygous familial hypercholesterolemia (HoFH) and hypercholesterolemia, including heterozygous familial hypercholesterolemic (HeFH) and atherosclerotic cardiovascular disease (ASCVD) patients on maximally tolerated statins, and severe hypertriglyceridemia (SHTG). The company was founded in 2008 and is headquartered in Livonia, Michigan.Helix BioPharmaOTCMKTS:HBPCFHelix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company is headquartered in Toronto, Canada.NeuBase TherapeuticsNASDAQ:NBSENeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.